2-Deoxy-D-glucose: Unlocking Metabolism–Cytoskeleton Crosstalk in Cancer and Virology

Introduction

The intersection of cellular metabolism and structural dynamics is rapidly emerging as a frontier in biomedical research. 2-Deoxy-D-glucose (2-DG)—a potent glycolysis inhibitor and metabolic oxidative stress inducer—is widely recognized for its roles in cancer therapy research and viral replication inhibition. Yet, recent advances reveal that its impact extends beyond simple metabolic disruption, forging new links between energy metabolism and cytoskeletal regulation. In this article, we explore 2-DG’s multifaceted mechanism of action, with a particular focus on its influence over the PI3K/Akt/mTOR signaling axis, cytoskeletal post-translational modifications, and the implications of these effects for translational oncology and virology research. This perspective expands upon and diverges from previous analyses, such as those focused on workflow protocols or immunometabolism, by integrating the latest findings on the metabolism–cytoskeleton interface.

Mechanism of Action of 2-Deoxy-D-glucose (2-DG)

Glycolysis Inhibition and ATP Synthesis Disruption

2-Deoxy-D-glucose (2-DG), available as APExBIO’s B1027 kit, is a synthetic glucose analog that functions as a competitive inhibitor of glycolysis. By mimicking glucose, 2-DG is taken up by glucose transporters and phosphorylated by hexokinase to 2-DG-6-phosphate, which cannot be further metabolized via glycolytic enzymes. This leads to a blockade of glycolytic flux, resulting in ATP synthesis disruption and the induction of metabolic oxidative stress in target cells. Such metabolic perturbation is central to 2-DG’s role as a metabolic pathway research tool, with direct implications for studies on energy homeostasis, cell viability, and stress responses.

PI3K/Akt/mTOR Signaling Pathway Modulation

Beyond glycolysis inhibition, 2-DG exerts downstream effects on the PI3K/Akt/mTOR signaling pathway, a master regulator of cell survival, proliferation, and metabolism. Decreased glycolytic intermediates and ATP levels alter PI3K/Akt/mTOR signaling, leading to reduced protein translation, cell growth, and proliferation. This is particularly relevant in cancer cells, which often exhibit heightened glycolytic activity and PI3K/Akt/mTOR pathway dependency.

Induction of Metabolic Stress and Cytotoxicity

By impeding glucose metabolism, 2-DG induces a state of metabolic oxidative stress. This stress is cytotoxic to cells reliant on aerobic glycolysis, such as many cancer phenotypes. Notably, 2-DG demonstrates potent effects against KIT-positive gastrointestinal stromal tumors (GISTs), with in vitro IC₅₀ values of 0.5 μM (GIST882) and 2.5 μM (GIST430). In animal models, 2-DG synergizes with chemotherapeutic agents (e.g., Adriamycin, Paclitaxel) to enhance tumor suppression in osteosarcoma and non-small cell lung cancer, underscoring its translational promise as a glycolysis inhibition agent in cancer research.

Metabolic Regulation of Cytoskeletal Dynamics: A New Paradigm

Connecting Glucose Metabolism to Microtubule Function

Traditionally, metabolic inhibitors like 2-DG have been associated with energy depletion and apoptosis. However, the cytoskeleton—particularly microtubules composed of α/β-tubulin heterodimers—has emerged as a direct downstream target of metabolic alterations. The seminal study by Lei Li et al. (2024) revealed that changes in intracellular lactate, a glycolytic byproduct, can modulate microtubule dynamics through HDAC6-catalyzed α-tubulin lactylation. Elevated lactate, induced by increased glycolytic activity, enhances α-tubulin lactylation at lysine 40, thereby promoting microtubule dynamics and neurite outgrowth in neuronal cells.

2-DG as a Tool for Dissecting Metabolism–Cytoskeleton Crosstalk

By inhibiting glycolysis, 2-DG reduces cellular lactate production, providing a unique opportunity to probe how metabolic flux influences cytoskeletal post-translational modifications (PTMs) such as lactylation and acetylation. As the cited Nature Communications paper demonstrates, these PTMs are central to regulating microtubule stability, intracellular transport, and cell migration—processes essential for cancer progression and virus-host interactions. 2-DG, therefore, serves not only as a metabolic oxidative stress inducer but also as a strategic modulator of cytoskeletal function in advanced research settings.

Implications for Cancer and Neuronal Research

The new understanding of α-tubulin lactylation—competing with acetylation on the same lysine residue—links cell metabolism to cytoskeleton function, impacting processes such as neurite branching, cell division, and tumor cell migration. In cancer research, targeting both glycolysis and cytoskeletal regulation using 2-DG may yield synergistic effects, inhibiting tumor proliferation and metastatic potential. This perspective goes beyond the established focus on immunometabolism (as discussed in this review), highlighting the untapped potential of 2-DG in modulating cellular infrastructure.

Comparative Analysis with Alternative Methods

2-DG versus Classic Glycolysis Inhibitors

While several glycolytic inhibitors exist, such as lonidamine and 3-bromopyruvate, 2-DG stands out due to its dual role as a 2-DG glycolysis inhibitor and metabolic oxidative stress inducer. Its water solubility (≥105 mg/mL) and compatibility with ethanol and DMSO make it versatile for in vitro and in vivo experimentation. The recommended treatment concentrations (5–10 mM for 24 hours) balance efficacy with manageable stress induction, unlike more aggressive agents prone to nonspecific cytotoxicity.

Beyond Energy Blockade: Unique Cytoskeletal Insights

Most existing analyses, such as the workflow-focused "Advanced Glycolysis Inhibition for Cancer & Viral Research", emphasize protocol optimization and immunometabolic targeting. This article, in contrast, foregrounds recent discoveries on cytoskeletal PTMs and metabolic regulation, moving beyond protocols to elucidate the fundamental biology underlying 2-DG’s effects. By doing so, it complements and extends the literature on 2-DG as a metabolic pathway research tool.

Advanced Applications in Cancer Research

KIT-positive Gastrointestinal Stromal Tumor (GIST) Treatment

2-DG’s ability to selectively induce metabolic stress in KIT-positive GIST cell lines, with low micromolar IC₅₀ values, underscores its promise as an adjunct to targeted therapies. Its mechanism—disrupting glycolysis and ATP synthesis—renders tumor cells more susceptible to standard-of-care agents, while its effects on cytoskeletal dynamics may further impair tumor invasiveness and metastatic capacity.

Non-Small Cell Lung Cancer Metabolism

In xenograft models of non-small cell lung cancer, 2-DG in combination with chemotherapeutics (Adriamycin, Paclitaxel) slows tumor growth more effectively than either agent alone. This synergism arises from simultaneous disruption of energy production and cytoskeleton-dependent processes like cell division and migration. Thus, 2-DG offers a multi-pronged approach to cancer therapy, targeting both metabolic and structural vulnerabilities.

Integration with Cytoskeletal Modulators

Given the link between glycolytic flux and α-tubulin PTMs, combining 2-DG with microtubule-targeting drugs (e.g., Taxol) may potentiate antitumor effects. Taxol is known to stabilize microtubules and enhance α-tubulin acetylation, while 2-DG may suppress competing lactylation, potentially shifting the balance toward microtubule stabilization and impaired cell motility. This integrative strategy represents a new direction in combinatorial oncology research.

Advanced Applications in Virology

Viral Replication Inhibition

Viruses rely heavily on host cell metabolism for replication and protein synthesis. 2-DG impairs viral protein translation during early replication stages, as shown in porcine epidemic diarrhea virus (PEDV) studies using Vero cells. By depleting ATP and reducing glycolytic intermediates, 2-DG interrupts the energy-intensive process of viral genome amplification and assembly. This antiviral effect is broad, offering potential utility against diverse pathogens.

Modulation of Host Cytoskeletal Functions

Many viruses hijack the host cytoskeleton to facilitate entry, intracellular trafficking, and egress. By modulating glycolysis and, consequently, cytoskeletal PTMs, 2-DG may indirectly disrupt these viral strategies. This layer of action distinguishes 2-DG from classic antivirals, which target viral proteins directly. These insights build upon but go beyond the focus on metabolic pathway modulation and translational applications presented in previous articles, by emphasizing the cytoskeletal dimension of viral inhibition.

Experimental Considerations and Best Practices

• Solubility: 2-DG is highly soluble (≥105 mg/mL in water), facilitating preparation of stock solutions for cell culture and in vivo studies. Ethanol and DMSO can be used with warming and ultrasonic treatment for more specialized applications.
• Storage: Store at -20°C; avoid long-term storage of solutions to preserve compound integrity.
• Dosage: Typical experimental concentrations are 5–10 mM for 24 hours, but these may be optimized based on cell type and research objectives.
• Controls: Always include appropriate vehicle and positive controls to distinguish specific metabolic and cytoskeletal effects.

Conclusion and Future Outlook

2-Deoxy-D-glucose (2-DG) is redefining the landscape of metabolic and cytoskeletal research. As a 2-DG glycolysis inhibitor and metabolic oxidative stress inducer, 2-DG from APExBIO offers unmatched versatility for probing the interconnectedness of cell metabolism, ATP synthesis, and cytoskeletal function. Recent discoveries—such as the metabolic regulation of α-tubulin lactylation (see Nature Communications, 2024)—underscore the importance of considering cytoskeletal dynamics alongside metabolic pathways in both cancer and virology research. By leveraging these insights, researchers can design more sophisticated experiments and develop combinatorial therapies targeting both metabolic vulnerabilities and structural dependencies of malignant and infected cells.

This article expands upon workflow and immunometabolic discussions found in previous literature by integrating the latest advances in metabolism–cytoskeleton crosstalk, providing a roadmap for next-generation research with 2-DG. As metabolic and structural biology converge, 2-DG stands as a cornerstone tool for unraveling the complex networks underpinning cellular health and disease.